ACCESS Newswire
10 Sep 2019, 17:49 GMT+10
MUNICH/MARTINSRIED, GERMANY / ACCESSWIRE / September 10, 2019 / Secarna Pharmaceuticals ('Secarna'), a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the terms of the agreement, the global top 10 pharmaceutical partner will utilize ASOs derived from Secarna's proprietary LNAplusTM platform in support of anti-cancer therapies the partner is developing and commercializing. Financial terms and the name of the partner were not disclosed. The LNAplusTM platform has been validated through numerous internal projects as well as multiple academic and industry collaborations such as with Firebrand Therapeutics, Lipigon Pharmaceuticals, and Met P Pharma.
'This first agreement with a large global pharmaceutical partner is a major milestone for Secarna and a crucial step in paving the path for a new generation of anti-cancer therapeutics,' said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals. 'The agreement is a further testament to our LNAplusTM approach of developing highly specific, safety-optimized and efficacious antisense oligonucleotide therapies for challenging targets.'
About Secarna's Proprietary Drug Discovery Platform, LNAplusTM
Secarna's proprietary third-generation antisense oligonucleotide (ASO) platform, LNAplusTM, which encompasses all aspects of drug discovery and pre-clinical development, enables the Company to discover novel antisense-based therapies for challenging or currently undruggable targets.Secarna's platform and ASOs have previously been validated by numerous in-house projects as well as in several academic and industry collaborations. With over 15 development programs focusing on targets and indications such as immuno-oncology, immunology, antiviral, fibrotic diseases, ophthalmology, neurodegenerative diseases and cardiometabolic diseases, where antisense-based approaches have clear benefits compared to other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna's mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide platform to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com
Contact:
Jonas Renz
Managing Director and Co-founder
[email protected]
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375
For media enquiries:
Anne Hennecke
MC Services AG
[email protected]
Tel.: +49 (0)211.52 92 52 22
The issuer is solely responsible for the content of this announcement.
SOURCE: Secarna Pharmaceuticals GmbH & Co. KG
Get a daily dose of Raleigh Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Raleigh Times.
More InformationGOODLETTSVILLE, Tennessee: Dollar General reported record sales of US$10.44 billion for the latest quarter and raised its full-year...
SOUTH BURLINGTON, Vermont: Beta Technologies has become the first U.S. company to land an all-electric aircraft at an airport in the...
WASHINGTON, D.C. Forget bucket lists; this summer, it's all about budget lists. Amid economic uncertainty and a weaker dollar, Americans...
MENLO PARK, California: As artificial intelligence demands explode, Big Tech is turning to an old source for new power: nuclear energy....
NEW YORK, New York - U.S. stocks rose appreciably Friday following the release of a strong jobs report which sent the U.S. dollar higher,...
WASHINGTON, D.C. America's job market is starting to lose momentum. In April, job openings rose — but so did layoffs, marking their...
New Delhi [India] June 6 (ANI): England seamer Mark Wood could 'potentially' return in Test four or five against India as he continues...
Chester-le-Street [UK], June 2 (ANI): England legendary pacer James Anderson made his return to T20 cricket for the first time in 11...
ABU DHABI, 16th May, 2025 (WAM) -- Etihad Airways has announced a new addition to its growing US network with the launch of non-stop...
RALEIGH, N.C. (CN) - Environmental groups sued the city of Asheboro, North Carolina, on Tuesday, claiming that it was collaborating...
Paul Gutierrez Jakobi Meyers is in an NFL offseason for the first time as his team's undisputed No. 1 wideout. He is coming off...
CHARLOTTE The more things change forPatrick Jones II, the more things stay the same. The veteran outside linebacker moved from Minnesota...